Jackson Creek Investment Advisors LLC Has $1.72 Million Stake in PTC Therapeutics, Inc. $PTCT

Jackson Creek Investment Advisors LLC trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 38.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,603 shares of the biopharmaceutical company’s stock after selling 14,113 shares during the quarter. Jackson Creek Investment Advisors LLC’s holdings in PTC Therapeutics were worth $1,717,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PTCT. Empowered Funds LLC acquired a new position in shares of PTC Therapeutics in the first quarter valued at $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of PTC Therapeutics by 11.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock valued at $9,109,000 after purchasing an additional 18,504 shares in the last quarter. Quantbot Technologies LP grew its position in PTC Therapeutics by 280.1% in the second quarter. Quantbot Technologies LP now owns 2,478 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 1,826 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in PTC Therapeutics in the second quarter valued at $1,661,000. Finally, EverSource Wealth Advisors LLC grew its position in PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 814 shares during the period.

PTC Therapeutics Stock Performance

Shares of PTCT stock opened at $67.65 on Wednesday. The stock’s fifty day moving average is $69.17 and its 200-day moving average is $72.42. The stock has a market capitalization of $5.61 billion, a PE ratio of -29.03, a PEG ratio of 12.83 and a beta of 0.53. PTC Therapeutics, Inc. has a 52 week low of $43.17 and a 52 week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.42. The company had revenue of $272.55 million for the quarter, compared to analysts’ expectations of $217.42 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The business’s revenue for the quarter was up 43.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $10.04 earnings per share. As a group, analysts forecast that PTC Therapeutics, Inc. will post 0.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

PTCT has been the topic of a number of analyst reports. TD Cowen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the company from $75.00 to $90.00 in a research report on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a research report on Friday, February 20th. Raymond James Financial initiated coverage on PTC Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $108.00 price target on the stock. Wells Fargo & Company upped their price target on PTC Therapeutics from $86.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Truist Financial upgraded PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.36.

Insider Activity at PTC Therapeutics

In other news, insider Neil Gregory Almstead sold 52,003 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $69.04, for a total transaction of $3,590,287.12. Following the sale, the insider owned 60,137 shares in the company, valued at approximately $4,151,858.48. This represents a 46.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 15,167 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $70.00, for a total value of $1,061,690.00. Following the sale, the director owned 8,000 shares in the company, valued at $560,000. The trade was a 65.47% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 115,022 shares of company stock valued at $7,925,979. 5.50% of the stock is currently owned by company insiders.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.